Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10880609 | 0.84 | CYP3A4 (0.32) | CYP3A4TSHRPIK3CA | |
| SCHEMBL8623385 | 0.81 | MAPT (0.39) | CYP3A4ALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL2525625 | 0.81 | L3MBTL1 (0.48) | CYP3A4TSHRALDH1A1NPC1GAA | |
| Hydrochloric Acid SCHEMBL10856519 | 0.79 | L3MBTL1 (0.46) | CYP3A4ALDH1A1NPC1GAARAB9A | |
| SCHEMBL10832383 | 0.79 | POLB (0.42) | CYP3A4ALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL5155034 | 0.79 | PARP10 (0.31) | ALDH1A1 | |
| SCHEMBL8626163 | 0.76 | TAAR1 (0.36) | CYP3A4TSHRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL5154211 | 0.76 | KDM4E (0.37) | GAA | |
| Bromide SCHEMBL6726492 | 0.75 | KDM4E (0.36) | GAA | |
| SCHEMBL8619688 | 0.73 | USP2 (0.45) | TSHRALDH1A1NPC1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | claimed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | claimed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | claimed |
| CN-1119148-C | Use of 'alpha' 1L agonists in treatment of incontinence | BOEHRINGER INGELHEIM KG (DE) | 2003-08-27 | — | — | CN | claimed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | claimed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | claimed |
| JP-3379960-B2 | — | — | 2003-02-24 | — | — | JP | claimed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | claimed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | claimed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | claimed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | claimed |
| US-8591947-B2 | Dual controlled release dosage form | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2013-11-26 | — | — | US | disclosed |
| US-20130108693-A1 | Dual Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2013-05-02 | — | — | US | disclosed |
| US-8329217-B2 | Dual controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2012-12-11 | — | — | US | disclosed |
| US-8241667-B2 | Dual controlled release osmotic device | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2012-08-14 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | CYP3A4 3857/4885TSHR 2606/4885PIK3CA 4180/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | CYP3A4 1909/4885TSHR 4526/4885PIK3CA 4154/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | CYP3A4 2807/4885TSHR 3011/4885PIK3CA 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.